Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Linaclotide (Linzess) vs Setmelanotide (Imcivree)
An educational, source-based comparison of Linaclotide (Linzess) and Setmelanotide (Imcivree) — how each peptide works, what it's researched for, and what to know before going deeper.
Guanylate cyclase-C agonist peptide for IBS-C and chronic constipation.
14-amino-acid peptide that activates intestinal guanylate cyclase-C, increasing cGMP and chloride/bicarbonate secretion into the gut lumen — accelerating transit and reducing visceral pain.
- IBS-C
- Chronic idiopathic constipation
- Functional constipation in children
- • FDA-approved.
- • Contraindicated in children <2 years; diarrhea common.
MC4R agonist for rare genetic obesity disorders.
Cyclic 8-amino-acid melanocortin-4 receptor (MC4R) agonist that restores signaling in the leptin–melanocortin pathway, addressing hyperphagia and obesity in specific genetic deficiencies (POMC, PCSK1, LEPR, Bardet–Biedl syndrome).
- POMC/LEPR/PCSK1 deficiency obesity
- Bardet–Biedl syndrome
- • FDA-approved.
- • Hyperpigmentation, injection-site reactions common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Linaclotide (Linzess) | Linaclotide phase 3 trials | NEJM | 2011 | Improved abdominal pain and bowel function in IBS-C. |
| Setmelanotide (Imcivree) | Setmelanotide phase 3 trials | Lancet Diabetes & Endocrinology | 2020 | Significant weight loss and hunger reduction in genetic obesity syndromes. |
Side-effect & safety grid
- FDA-approved.
- Contraindicated in children <2 years; diarrhea common.
- FDA-approved.
- Hyperpigmentation, injection-site reactions common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Linaclotide (Linzess) vs Setmelanotide (Imcivree) — Key differences
- Class: Linaclotide (Linzess) is classified as GC-C Agonist · Gastrointestinal, while Setmelanotide (Imcivree) is Melanocortin Agonist · Metabolic.
- Primary research focus: Linaclotide (Linzess) — ibs-c; Setmelanotide (Imcivree) — pomc/lepr/pcsk1 deficiency obesity.
- Tag: FDA-Approved · GI vs FDA-Approved · Rare Disease.